Kinase Inhibitors
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma
International Journal of Oncology 2017 May [Epub ahead of print] [Link] Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer for which more effective treatments are needed. In this…
Read MoreThe inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells
Stem cell research & therapy 2017 May 25 [Link] Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A Abstract BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after…
Read MoreProstaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer
Oncoimmunology 2016 December [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28344879″>Link] Al-Taei S, Salimu J, Spary LK, Clayton A, Lester JF, Tabi Z Abstract CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a highly regulated, serial manner into ADP, AMP and adenosine. The end product, adenosine, has both tumor-promoting and immunosuppressive effects. The aim of this study was to…
Read MoreThe Immune Microenvironment, Genome -Wide Copy Number Aberrations and Survival in Mesothelioma
Journal of Thoracic Oncology 2017 February [Epub ahead of print] [Link] Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, Mitchell P, Watkins DN, Boutros PC, John T Abstract INTRODUCTION: Results of recent clinical studies of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM)…
Read MoreA phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group
Lung Cancer (Netherlands) 2017 February [Epub 2016 December 15] [Link] Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN Abstract OBJECTIVES: Following failure of a platinum-antifolate combination regimen, there is no standard therapy for advanced malignant pleural mesothelioma (MPM). The…
Read MoreTunneling nanotubes: an alternate route for propagation of the bystander effect following oncolytic viral infection
Molecular Therapy Oncolytics 2016 December [Link] Ady J, Thayanithy V, Mojica K, Wong P, Carson J, Rao P, Fong Y, Lou E Abstract Tunneling nanotubes (TNTs) are ultrafine, filamentous actin-based cytoplasmic extensions which form spontaneously to connect cells at short and long-range distances. We have previously described long-range intercellular communication via TNTs connecting mesothelioma cells…
Read MorePromising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts
International Journal of Cancer 2017 January [Epub 2016 September 19] [Link] Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D’Incalci M, Frapolli R Abstract It has recently been reported that a large proportion…
Read MoreAccelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fibers
International Journal of Oncology 2016 November 22 [Epub ahead of print] [Link] Lee S, Matsuzaki H, Maeda M, Yamamoto S, Kumagai-Takei N, Hatayama T, Ikeda M, Yoshitome K, Nishimura Y, Otsuki T Abstract Asbestos exposure causes malignant tumors such as lung cancer and malignant mesothelioma. Based on our hypothesis in which continuous exposure to asbestos…
Read MoreA Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
Journal of Thoracic Oncology 2016 November [Epub 2016 July 20] [Link] Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA Abstract There is no approved second-line systemic therapy option for malignant pleural mesothelioma (MPM), but targeting…
Read MoreEpithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework
Oncotarget 2016 September 26 [Epub ahead of print] [Link] Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S Abstract The aim of this study was to reconsider the…
Read More